Company Description
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need.
The company’s lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.
It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications.
In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area.
Equillium, Inc. has a research collaboration agreement with Vivtex Corporation to develop GI-targeted formulations for Bi-specific peptide therapy.
The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017.
Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
| Country | United States |
| Founded | 2017 |
| IPO Date | Oct 11, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 44 |
| CEO | Bruce Steel |
Contact Details
Address: 2223 Avenida De La Playa, Suite 105 La Jolla, California 92037 United States | |
| Phone | 858 240 1200 |
| Website | equilliumbio.com |
Stock Details
| Ticker Symbol | EQ |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001746466 |
| CUSIP Number | 29446K106 |
| ISIN Number | US29446K1060 |
| Employer ID | 82-1554746 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Bruce D. Steel C.F.A. | Co-Founder, President, Chief Executive Officer and Director |
| Daniel Mark Bradbury | Executive Chairman |
| Christine Zedelmayer M.B.A., P.M.P. | Senior Vice President and Chief Operating Officer |
| Dr. Stephen Connelly Ph.D. | Chief Scientific Officer and Director |
| Jason A. Keyes | Chief Financial Officer |
| Penny Tom | Senior Vice President of Finance and Principal Accounting Officer |
| Michael Moore | Vice President of Investor Relations and Corporate Communications |
| Dr. Matthew Ritter Ph.D. | Senior Vice President of Corporate Development |
| Joel M. Rothman | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 13, 2024 | 8-K | Current Report |
| Dec 12, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 144 | Filing |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Oct 31, 2024 | 144 | Filing |
| Oct 31, 2024 | 8-K | Current Report |
| Oct 31, 2024 | 8-K | Current Report |
| Aug 8, 2024 | 10-Q | Quarterly Report |